Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma
Creators
- 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (United States)
- 2. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (United States)
- 3. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (United States)
- 4. Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, TX (United States)
Description
Purpose: The goal of this study was to evaluate dosimetric parameters, acute toxicity, pathologic response, and local control in patients treated with preoperative intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for localized gastric adenocarcinoma. Methods: Between November 2007 and April 2010, 25 patients with localized gastric adenocarcinoma were treated with induction chemotherapy, followed by preoperative IMRT and concurrent chemotherapy and, finally, surgical resection. The median radiation therapy dose was 45 Gy. Concurrent chemotherapy was 5-fluorouracil and oxaliplatin in 18 patients, capecitabine in 3, and other regimens in 4. Subsequently, resection was performed with total gastrectomy in 13 patients, subtotal gastrectomy in 7, and other surgeries in 5. Results: Target coverage, expressed as the ratio of the minimum dose received by 99% of the planning target volume to the prescribed dose, was a median of 0.97 (range, 0.92–1.01). The median V30 (percentage of volume receiving at least 30 Gy) for the liver was 26%; the median V20 (percentage of volume receiving at least 20 Gy) for the right and left kidneys was 14% and 24%, respectively; and the median V40 (percentage of volume receiving at least 40 Gy) for the heart was 18%. Grade 3 acute toxicity developed in 14 patients (56%), including dehydration in 10, nausea in 8, and anorexia in 5. Grade 4 acute toxicity did not develop in any patient. There were no significant differences in the rates of acute toxicity, hospitalization, or feeding tube use in comparison to those in a group of 50 patients treated with preoperative three-dimensional conformal radiation therapy with concurrent chemotherapy. R0 resection was obtained in 20 patients (80%), and pathologic complete response occurred in 5 (20%). Conclusions: Preoperative IMRT for gastric adenocarcinoma was well tolerated, accomplished excellent target coverage and normal structure sparing, and led to appropriate pathologic outcomes.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2011.07.035Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2011.07.035;
- PII
- S0360-3016(11)03106-3;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 83
- Journal Issue
- 2
- Journal Page Range
- p. 581-586
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44016769
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANOREXIA; CARCINOMAS; CHEMOTHERAPY; GASTRECTOMY; HEART; KIDNEYS; LIVER; NAUSEA; PATIENTS; PLANNING; RADIATION DOSES; RADIOTHERAPY; TOXICITY; URACILS
- Descriptors DEC
- AZINES; BODY; CARDIOVASCULAR SYSTEM; DIGESTIVE SYSTEM; DISEASES; DOSES; GLANDS; HETEROCYCLIC COMPOUNDS; HYDROXY COMPOUNDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PYRIMIDINES; RADIOLOGY; SURGERY; SYMPTOMS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.